BMY - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154
United States
212-546-4000
http://www.bms.com
Sector: Healthcare
Industry: Drug Manufacturers - Major
Full Time Employees: 23,700
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Giovanni Caforio | Chairman & CEO | 5.11M | 3.17M | 1965 |
| Mr. Charles A. Bancroft | Exec. VP of Global Bus. Operations & CFO | 2.85M | N/A | 1960 |
| Dr. Thomas J. Lynch Jr. | Exec. VP of R&D & Chief Scientific Officer | 152.5k | N/A | 1961 |
| Ms. Sandra Leung | Exec. VP & Gen. Counsel | 2.45M | 5.17M | 1961 |
| Mr. Joseph C. Caldarella | Sr. VP, Corp. Controller & Principal Accounting Officer | N/A | N/A | 1956 |
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Corporate Governance
Bristol-Myers Squibb Company’s ISS Governance QualityScore as of September 1, 2018 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 5.
